Pharmacological dose ascorbic acid administration in relapsed refractory multiple myeloma patients [0.03%]
大剂量维生素C治疗复发难治多发性骨髓瘤患者的临床研究
Ali Zahit Bolaman,Atakan Turgutkaya,Hilal Eroğlu Küçükdiler et al.
Ali Zahit Bolaman et al.
Objective: High-dose ascorbic acid leads to the formation of highly reactive oxygen species due to the pro-oxidant effect, resulting in cell death; therefore, used as an additive treatment in several malignancies. We pres...
Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey [0.03%]
吉妥珠单抗奥佐米星在复发难治急性髓系白血病中的应用：来自土耳其的多中心真实世界数据
Ayşe Hilal Eroğlu Küçükdiler,İrfan Yavaşoğlu,Cem Selim et al.
Ayşe Hilal Eroğlu Küçükdiler et al.
We retrospectively evaluated the use of gemtuzumab ozogamicin (GO) in relapsed refractory (R/R) acute myeloid leukemia (AML) patients. Twenty-one CD33 positive R/R AML patients who received GO as a single agent in 4 hematology centers were ...
Eosinophilia characterized by a rare CCT6B mutation and responsive to tyrosine kinase inhibition: Case report and literature review [0.03%]
由罕见的CCT6B突变表征并对酪氨酸激酶抑制有反应的嗜酸性粒细胞增多症：病例报告及文献回顾
Abhay Singh,Jeffrey Baron,Namrata Singh et al.
Abhay Singh et al.
Hypereosinophilic syndrome is a rare disorder arising from neoplastic, or idiopathic causes. The availability of NGS panels has increasingly identified rare mutations as underlying pathogenic events and have led to reclassification of cases...
Promising remissions in relapsed refractory classical Hodgkin lymphoma patients requiring multiple salvage regimens before transplantation in the brentuximab vedotin era [0.03%]
在 Brentuximab vedotin 时代，移植前需要多次挽救方案的经典霍奇金淋巴瘤患者的复发难治获得有希望的缓解
Khadega A Abuelgasim,Samer Ghazi,Bader Alahmari et al.
Khadega A Abuelgasim et al.
Relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients refractory to first line salvage have poor outcomes. Herein we report the outcome of R/R cHL patients requiring ≥two vs. one line in the era of chemo-immunotherapy. Among 55...
Successful allogeneic bone marrow transplantation after massive gastrointestinal bleeding in a patient with myelodysplastic syndrome associated with intestinal Behçet-like disease [0.03%]
与肠道贝赫切特病样疾病相关的骨髓增生异常综合征患者出现大量胃肠出血后异基因骨髓移植成功的病例报告
Arata Ishii,Shokichi Tsukamoto,Tatsuzo Mishina et al.
Arata Ishii et al.
A 45-year-old woman was diagnosed with myelodysplastic syndrome (MDS) with trisomy 8 and Behçet-like disease (BLD) with multiple colorectal ulcers. Nonspecific inflammatory cells were infiltrated in the intestinal mucosa, whereas fluoresce...
Patrick Willard,John McKay,Victor Yazbeck
Patrick Willard
Monoclonal antibodies (mAb) for indolent non-Hodgkin's lymphoma (iNHL) including follicular and marginal zone lymphomas was a key therapeutic development that changed the natural history of these diseases. Rituximab, a chimeric anti-CD20 mA...
Pediatric M5 acute myeloid leukemia with MLL-SEPT6 fusion and a favorable outcome [0.03%]
具有MLL-SEPT6融合基因且预后良好的儿童M5型急性髓系白血病
Alain Chebly,Claudia Djambas Khayat,Tony Yammine et al.
Alain Chebly et al.
Acute myeloid leukemia (AML) patients with MLL-SEPT6 fusion represent a small subset of AML. The uncommon MLL-SEPT6 rearrangement results from t(X;11) or other variants like ins(X;11), and it is usually associated with complex cytogenetic a...
Prognostic factors affecting the outcome after allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome [0.03%]
异基因造血干细胞移植治疗骨髓增生异常综合征的预后因素
P Belohlavkova,F Vrbacky,L Smolej et al.
P Belohlavkova et al.
In the present study, we retrospectively analysed the results of HSCT in 47 consecutive patients with MDS diagnosed at our department between 2002 and 2019, with a focus on possible predictive factors influencing overall survival (OS), the ...
Evidence of two different molecular mechanisms as a consequence of an isolated 20q- abnormality in a case of multiple myeloma accompanied with myelodysplastic syndrome [0.03%]
具有伴随骨髓增生异常综合征的多发性骨髓瘤中单纯20q-异常的两种不同分子机制证据
Lubomir Mitev
Lubomir Mitev
The deletion of the long arm of chromosome 20 is a characteristic cytogenetic marker of myeloid disorders. Rarely, it is also found in lymphoproliferative diseases, including multiple myeloma (MM). The role of 20q- in MM is not fully unders...
Treatment outcome of doxorubicin versus idarubicin in adult acute myeloid leukemia [0.03%]
成人急性髓系白血病阿霉素与伊达比星治疗结果的研究
Hemat Afifi Sherif,Ahmed Magdy,Heba Anees Elshesheni et al.
Hemat Afifi Sherif et al.
Purpose: The present study aimed to compare treatment outcome of idarubicin versus doxorubicin in combination with Ara-C as induction therapy for untreated AML patients. ...